Journal of VitreoRetinal Diseases最新文献

{"title":"Intraocular Inflammation, Safety Events, and Outcomes After Intravitreal Injection of Ranibizumab, Aflibercept, Brolucizumab, Abicipar Pegol, and Faricimab for nAMD.","authors":"Marta Stevanovic, Nicole Koulisis, Tom Chen, Stavros N Moysidis, Bruce Burkemper, Brian C Toy, Narsing A Rao, Dean Eliott, Mark S Humayun","doi":"10.1177/24741264251332515","DOIUrl":"https://doi.org/10.1177/24741264251332515","url":null,"abstract":"<p><p><b>Purpose:</b> To compare the rates of intraocular inflammation (IOI) in patients with neovascular age-related macular degeneration (nAMD) after injection of intravitreal (IVT) antivascular endothelial growth factor drugs. <b>Methods:</b> This study included all phase 3 randomized clinical trials of patients with nAMD treated with ranibizumab, aflibercept, brolucizumab, abicipar pegol, or faricimab. The outcomes assessed were the incidence of IOI, retinal artery occlusion (RAO), retinal vasculitis and choroiditis, endophthalmitis, and serious systemic adverse events (AEs) as well as the change in visual acuity (VA) (Early Treatment Diabetic Retinopathy Study letters) and in central retinal thickness (CRT). <b>Results:</b> Abicipar pegol was associated with a higher incidence of IOI than aflibercept, ranibizumab, faricimab, and sham injections, while brolucizumab was associated with a higher rate of IOI than aflibercept, faricimab, and sham injections. Abicipar pegol was also associated with a higher rate of endophthalmitis than aflibercept. Significantly more retinal vasculitis and choroiditis was seen with abicipar pegol and brolucizumab than with ranibizumab and aflibercept, respectively, and RAOs occurred more frequently with abicipar pegol and brolucizumab than with ranibizumab and aflibercept, respectively. There were no differences in the change in VA among the drugs. Treatment with brolucizumab resulted in a greater change in CRT than with abicipar pegol, aflibercept, ranibizumab, and faricimab, while treatment with faricimab resulted in a greater change in CRT than aflibercept and ranibizumab. Faricimab was associated with fewer serious systemic AEs than aflibercept. <b>Conclusions:</b> Abicipar pegol and brolucizumab were associated with a higher incidence of ocular AEs in phase 3 randomized controlled trials. The potential benefits of these drugs should be weighed against the AEs.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251332515"},"PeriodicalIF":0.5,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12012493/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144042611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peer-Review Essentials: Reviewing Manuscripts for the <i>Journal of VitreoRetinal Diseases</i>.","authors":"Eric Jung, Aleksandra Rachitskaya, Yoshihiro Yonekawa, Timothy G Murray","doi":"10.1177/24741264251331647","DOIUrl":"https://doi.org/10.1177/24741264251331647","url":null,"abstract":"<p><p>The thoughtful process of peer review allows for the vetting and improvement of scientific work that leads to quality research and, eventually, advancement of the field of retina. Progress in medicine would not occur without dedicated researchers, but just as important are the peer reviewers who take the time assess their work, weigh in on their validity, and help bring these papers to life. Here, we discuss how to effectively review a journal manuscript in a way that helps both the beginning reviewer and the seasoned expert develop a framework to provide meaningful peer review. Although this guide was specifically written with <i>JVRD</i> aims in mind, these suggestions can be broadly applied to the process of manuscript review in general.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251331647"},"PeriodicalIF":0.5,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple Successive Branch Retinal Artery Occlusions in a Patient With Antiphospholipid Syndrome Despite Anticoagulation.","authors":"Samantha R Goldburg, Albert S Li","doi":"10.1177/24741264251331638","DOIUrl":"https://doi.org/10.1177/24741264251331638","url":null,"abstract":"<p><p><b>Purpose:</b> To describe a patient with antiphospholipid syndrome presenting with branch retinal artery occlusions (BRAO) despite anticoagulation. <b>Methods:</b> A single case was evaluated. <b>Results:</b> A 53-year-old woman with antiphospholipid syndrome on anticoagulation presented for a routine ophthalmic examination. She had no visual complaints, and the visual acuity was 20/25^-1 OD and 20/30^-1 OS. A BRAO was found in the right eye. Despite treatment with aspirin, warfarin, prednisone, plasmapheresis, and rituximab, multiple new occlusions were found when the patient returned the next month. She ultimately had a stroke, which led to her death. <b>Conclusions:</b> This case underscores the importance of interdisciplinary care for patients with antiphospholipid syndrome presenting with BRAOs despite anticoagulation.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251331638"},"PeriodicalIF":0.5,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11994628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144030055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Switch to Aflibercept After Chronic Treatment With Bevacizumab for Choroidal Neovascularization With Age-Related Macular Degeneration.","authors":"Zofia Anna Nawrocka, Karolina Dulczewska-Cichecka, Michal Zając, Thomas A Galus, Magdalena Trębinska, Jerzy Nawrocki","doi":"10.1177/24741264251330334","DOIUrl":"https://doi.org/10.1177/24741264251330334","url":null,"abstract":"<p><p><b>Purpose:</b> To present the 5-year anatomic and functional outcomes in patients with choroidal neovascularization (CNV) and age-related macular degeneration (AMD) and determine whether late-onset intensification of treatment results in improved outcomes. <b>Methods:</b> This retrospective interventional study analyzed spectral-domain optical coherence tomography data and visual acuity (VA) in eyes where treatment intensification was implemented after a mean of 39 months. Data collected included age, sex, injection frequency, central retinal thickness, type of CNV, and VA. Patients were evaluated every 4 to 10 weeks, depending on the disease activity. <b>Results:</b> Fifty eyes of 50 patients with CNV were evaluated. The mean initial VA was 0.37 Snellen (0.58 logMAR), which improved to 0.44 Snellen (0.47 logMAR) after the first bevacizumab injection. Six months after bevacizumab was switched to aflibercept, the improvement in VA was significant in all groups (<i>P</i> < .05). The VA improved throughout the 6-year observation period, with the greatest improvement in VA after the switch seen in patients who received the most injections (<i>P</i> < .05), had the best initial VA (<i>P</i> < .05), and who experienced a significantly greater improvement in VA after the first bevacizumab injection (<i>P</i> = .01). <b>Conclusions:</b> Increasing the treatment frequency, even after several years of treatment, improved visual outcomes in patients with CNV and AMD who switched from bevacizumab to aflibercept.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251330334"},"PeriodicalIF":0.5,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11993555/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Possible Association Between Dopamine Antagonists and Increased Conversion to Exudative Age-Related Macular Degeneration.","authors":"Peter J Weng, Richard Morgan, Dilraj S Grewal, Sharon Fekrat","doi":"10.1177/24741264251330338","DOIUrl":"10.1177/24741264251330338","url":null,"abstract":"<p><p><b>Purpose:</b> To investigate whether modulating dopamine signaling affects conversion to exudative age-related macular degeneration (AMD). <b>Methods:</b> A retrospective cohort study was performed using the Duke Epic database. Eyes from patients with a diagnosis of nonexudative AMD with at least 1 year of follow-up were evaluated for conversion to exudative AMD. Eyes with an AMD diagnosis were evaluated for age, sex, smoking history, hypertension, Age-Related Eye Disease Study (AREDS) or AREDS2 prescription, dopamine-modulating therapy prescription, and indication for dopamine-modulating therapy. Generalized estimating equations were used to calculate odds ratios for individual variables on conversion from nonexudative to exudative AMD. <b>Results:</b> Five hundred fifty-eight eyes of 354 patients with an initial diagnosis of nonexudative AMD were evaluated for conversion to exudative AMD. Conversion to exudative AMD was significantly higher in patients who had been on dopamine antagonist therapies for at least 3 years than in patients who were not on any dopamine-modulating therapies. After controlling for other variables, dopamine antagonists were associated with an increased risk for conversion to exudative AMD at 3 years of follow-up (<i>P</i> = .005). <b>Conclusions:</b> These findings suggest that antagonizing dopamine signaling may be associated with the development of macular neovascularization in eyes with nonexudative AMD. Although the data are observational, these findings warrant further investigation of dopamine signaling in conversion to exudative AMD.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251330338"},"PeriodicalIF":0.5,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11966630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative Methotrexate to Reduce Reoperation Rate and Improve Vision in Patients With Complex Retinal Detachments, Advanced Diabetic Retinopathy, and Trauma.","authors":"Lauren Gibson, Alyson Nguyen, Jared Ridgeway, Mariam Omar, Christopher Purvis, Yazen Shihab, Christopher D Riemann, Alan J Franklin","doi":"10.1177/24741264251323305","DOIUrl":"10.1177/24741264251323305","url":null,"abstract":"<p><p><b>Purpose:</b> To identify the potential benefits of postoperative intravitreal (IVT) methotrexate (MTX) for proliferative vitreoretinopathy (PVR), trauma, or advanced diabetic retinopathy (DR). <b>Methods:</b> A retrospective chart review was performed of previously unoperated eyes at high risk for failure as a result of preexisting PVR, trauma, or advanced DR. Patients were included who had retinal detachment (RD) surgery for the following reasons: failed previous retinal reattachment surgery, advanced proliferative DR (PDR), initial surgery for RD associated with trauma, or primary RD associated with grade C PVR. MTX 200 to 400 µg was administered intravitreally at postoperative weeks 1, 2, 4, 7, and 11. Data analyzed included the reoperation rate, visual acuity (VA), physical examination findings, and optical coherence tomography biomarkers. <b>Results:</b> Of the 255 eyes evaluated, 94 received IVT MTX (MTX group) and 161 eyes did not (control group). The mean number of reoperations was 0.39 in the MTX group and 0.94 in the control group (<i>P</i> < .01). The MTX group had a mean gain in VA of 1 line, while the control group had a mean loss of 2.9 lines (<i>P</i> < .01). <b>Conclusions:</b> Postoperative IVT MTX in eyes with advanced PDR or complicated RD yields comparable effective results, including reduced reoperation rates and improved VA.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251323305"},"PeriodicalIF":0.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915221/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Issues in Medicine: Equity and Site Neutrality.","authors":"","doi":"10.1177/24741264251322832","DOIUrl":"10.1177/24741264251322832","url":null,"abstract":"","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":"9 2","pages":"125-130"},"PeriodicalIF":0.5,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143657635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suprachoroidal Injection of Tattoo Ink.","authors":"Carson C Petrash, R Gary Lane","doi":"10.1177/24741264251324972","DOIUrl":"https://doi.org/10.1177/24741264251324972","url":null,"abstract":"<p><p><b>Purpose:</b> To describe a case of injection of tattoo dye into the suprachoroidal space. <b>Methods:</b> A single case and its findings were analyzed. <b>Results:</b> A 40-year-old man with a recent history of scleral tattooing presented for evaluation of right-sided blurry vision. An examination of the right eye showed slightly decreased acuity and pupillary response in the right eye compared with the left eye as well as black ink not only in the bilateral subconjunctival spaces but also in the suprachoroidal space. Remarkably, there was no apparent inflammatory reaction. The patient was followed for 8 months after the scleral tattooing procedure and never developed inflammatory sequelae. <b>Conclusions:</b> Suprachoroidal injection of dye is a potential complication of eyeball tattooing. Infection and noninfectious inflammation are common concerns, but some patients may tolerate the dye surprisingly well.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251324972"},"PeriodicalIF":0.5,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143649561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vitreoretinal Involvement in Patients With Fungemia at a Tertiary Care Hospital.","authors":"Carl S Wilkins, Karina Esquenazi, Kyle Hirabayashi, Jeffrey Brown, Rupak Bhuyan, Niathi Kona, Alexander Barash, Robin B Ginsburg, Avnish Deobhakta, Gareth M Lema","doi":"10.1177/24741264251321366","DOIUrl":"https://doi.org/10.1177/24741264251321366","url":null,"abstract":"<p><p><b>Purpose:</b> To identify the prevalence of fungal ophthalmic involvement and evaluate risk factors for positive screening for inpatients at an academic tertiary care hospital by assessing a priori screening criteria that may determine which patients need ophthalmic evaluation. <b>Methods:</b> This retrospective cohort study comprised patients with a documented positive blood culture for fungemia and an ophthalmic screening examination from January 1, 2015, to September 30, 2019. Ophthalmology notes and laboratory results taken during admission were evaluated. The primary outcomes were ocular involvement, presence of visual complaints, and duration of blood culture positivity. Variables assessed included recent gastrointestinal surgery, organ transplantation, HIV infection, diabetes mellitus, intravenous drug use, and central venous access. Analyses, including the Student <i>t</i> test, χ² test, and logistic regression, were performed. <b>Results:</b> Of 291 patients with fungemia, 7 had ocular involvement (3 with chorioretinitis; 4 with endophthalmitis). One patient with endophthalmitis required an intravitreal antifungal injection. No patient with chorioretinitis required injections or surgery. The mean culture positivity length was 5 days for those with vitreoretinal involvement and 4 days for those without vitreoretinal involvement (<i>P</i> > .05). Of patients with ocular involvement, 40.0% had a visual complaint compared with 4.2% without ocular involvement (<i>P</i> < .05). The negative predictive value was 99.3% for patients without complaints or persistent fungemia. <b>Conclusions:</b> Patients with visual complaints at the time of a positive blood culture for fungemia are at risk for ocular disease and require screening.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251321366"},"PeriodicalIF":0.5,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143649563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study.","authors":"Ashish Sharma, Frank G Holz, Nilesh Kumar, David Sarraf, Seemantini Ayachit, Chitaranjan Mishra, Adnan Tufail, Debdulal Chakraborty, Aleksandra Rachitskaya, David Eichenbaum, Alay Banker, Nikulaa Parachuri, Ashish Kumar, Anat Loewenstein, Francesco Bandello, Taku Wakabayashi, Se Joon Woo, Baruch D Kuppermann","doi":"10.1177/24741264251322213","DOIUrl":"https://doi.org/10.1177/24741264251322213","url":null,"abstract":"<p><p><b>Purpose:</b> To evaluate the early real-world clinical outcomes regarding the safety and efficacy after administration of a ranibizumab biosimilar (Ranieyes). <b>Methods:</b> This multicenter retrospective uncontrolled observational study incorporated data from 7 centers in India. All patients were treated with at least 1 intravitreal injection of 0.5 mg of ranibizumab biosimilar between July 2022 and July 2023 for various indications. <b>Results:</b> A total of 474 ranibizumab biosimilar injections were given in 268 eyes of 254 patients. Indications were diabetic macular edema (DME) (n = 112), macular neovascularization (MNV) (n = 92), retinal vein occlusion (RVO) (n = 54), cystoid macular edema (n = 4), and proliferative diabetic retinopathy with vitreous hemorrhage (n = 6). The mean logMAR BCVA (±SD) improved significantly from baseline to the last follow-up as follows: DME cases, from 0.77 ± 0.37 (Snellen equivalent, 6/36) to 0.43 ± 0.25 (6/15) (<i>z</i> = -8.0; <i>r</i> = -0.8); MNV cases, from 0.95 ± 0.53 (6/60) to 0.59 ± 0.42 (6/24) (<i>z</i> = -7.1; <i>r</i> = -0.8); RVO cases, from 0.83 ± 0.40 (6/45) to 0.44 ± 0.32 (6/15) (<i>z</i> = -5.5; <i>r</i> = -0.8) (all <i>P</i> < .001). All groups also had significant improvement in the central subfield thickness (all <i>P</i> < .001). No site reported drug-related adverse events (eg, inflammation, vasculitis, systemic adverse effects). <b>Conclusions:</b> The preliminary real-world data from this limited early series suggest that Ranieyes has clinical efficacy and is safe as a ranibizumab biosimilar across the approved indications.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251322213"},"PeriodicalIF":0.5,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869221/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143541839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}